Aquatic Capital Management tripled its stake in CVS Health during Q4, scooping up over 750,000 shares and elevating it to ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Fintel reports that on April 30, 2025, Leerink Partners downgraded their outlook for Quanterix (NasdaqGM:QTRX) from ...

Fintel reports that on April 30, 2025, Leerink Partners downgraded their outlook for NeoGenomics (NasdaqCM:NEO) from ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Leerink notes that Equillium (EQ) announced that the FDA declined to support an accelerated approval pathway for itolizumab in first-line ...

Leerink Partners analyst Puneet Souda maintained a Hold rating on 908 Devices (MASS – Research Report) on April 22. The company’s shares closed ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

Perella Weinberg Partners has hired Leerink Partners’ global co-head of investment banking Barry Blake, according to people with knowledge of the matter. Blake is set to join Perella after a ...

Perella Weinberg Partners has hired Leerink Partners ’ global co-head of investment banking Barry Blake, according to people with knowledge of the matter. Blake is set to join Perella after a period ...

On Tuesday, Leerink Partners maintained its Outperform rating on CVS Health (NYSE:CVS) shares with a steady price target of $75.00. According to InvestingPro data, CVS Health, currently trading at $63 ...